Spectrum of paraneoplastic disease associated with XXXX .

@entity1 @entity706 @entity8954 @entity16 @entity37229 @entity1893 @entity1971 @entity978 @entity528
OBJECTIVE: To define the frequency and clinical and immunologic characteristics of @entity1 affected by @entity16 ( @entity16 ) and @entity706 . METHODS: @entity1 fulfilling the criteria for @entity16 associated with @entity706 collected from the European Commission-funded @entity16 Euronetwork group database were analyzed. RESULTS: Fifty-three @entity1 with @entity978 ( @entity978 ) (24 @entity1 , mean age 51, range 16-84) or @entity1893 ( @entity1893 ) (29 @entity1 , mean age 64, range 31-82) and @entity16 were analyzed. The most commonly associated @entity16 was @entity37229 , present in 21 cases, with a higher prevalence in @entity978 (16/24 cases). Peripheral nervous system (mainly demyelinating @entity1971 ) and motor neuron involvement were more common in @entity1893 . Onconeural antibodies were more frequent in @entity1 with @entity37229 , most commonly against the Tr antigen. Fifty percent of the @entity1 with @entity16 and @entity978 responded to chemotherapy, whereas neurologic improvement was less frequent (24%) in @entity1 with @entity16 and @entity1893 . In both groups, the survival rate was good. Overall, 10 out of 53 @entity1 eventually died, with only 2 @entity1 (1 with @entity978 , 1 with @entity1893 ) dying from @entity16 . CONCLUSIONS: @entity16 in @entity1 with @entity706 are relatively rare. @entity37229 , mainly associated with anti-Tr antibodies, is more prevalent in @entity978 and @entity1893 , followed in our study by motor @entity528 in @entity1 with @entity1893 . Involvement of the peripheral nervous system is heterogeneous, with a prevalence of @entity8954 in @entity1 with @entity1893 .
